Our commitment to you is quality care.
The Care4ward story has its roots in a body of research that looked at what was different about long-tail survivors of cancers, those patients who beat the statistics in terms of survivorship. We were excited to uncover a robust body of evidence, including numerous clinical trials across patient populations with different types of cancer, that showed the positive impact of personalized nutrition intervention on treatment outcomes. It has become the mission of the Care4ward team to bring awareness of this adjuvant therapy to the medical community and our healthcare system; to give access to personalized medical nutrition therapy as a standard part of every cancer patient’s treatment plan. The Care4ward program is perfectly aligned with the advances of personalized medicine that include new diagnostic and informatics approaches, all with the goal of supporting quality of life for patients facing a future with cancer.
Board of Directors
Mike Cotton joined Providence Health Plan as chief executive officer in 2015. With more than 25 years’ experience in healthcare, Mike provides strategic leadership for Providence Health Plan’s commercial, self-funded, Medicare and Medicaid programs, which currently serve more than 500,000 members.
Before joining Providence Health Plan, Mike was vice president and chief operating officer for Humana, responsible for their Medicaid and state-based contract programs. Prior to Humana, Mike held executive management roles with Evolent Health and Alere Health. In addition, Mike has led provider-sponsored health plans affiliated with University Hospitals Health System and Premier Health System.
Cotton graduated from Cleveland State University, earning an MBA in healthcare administration. Cotton also holds a certificate of executive healthcare management from Case Western Reserve University and completed his undergraduate studies at Franklin University and The Ohio State University in Columbus, Ohio.
Patrick F. Cua
Pat Cua has thirty years of healthcare leadership experience ranging from large Fortune 500 companies to startups focused on solutions for hospitals and health plans. His industry experience began with C.R. Bard and has included executive leadership positions with CorSolutions, Matria Healthcare, Aetna, and Alere.
In addition to his role as president and CEO of Healthstar Growth Partners, he also serves on the board of directors of several other successful, high-growth healthcare technology companies. He is currently serving as chairman of the board with BioIQ in Santa Barbara, California, and serves as a board member for Kaviva in Houston, Texas, Gozio Health in Atlanta, Georgia, and Glytec in Waltham, Massachusetts
Our Advisory Board
Pete Desai has an extensive background in developing and implementing innovative healthcare programs and services within both small and large organizations. Currently, he serves as the Chief Operating Officer of BioIQ, a healthcare technology company enabling payors to close gaps in care. Pete started with Accenture where he helped define corporate strategy and growth plans for clients. After a move to Alere Health, Pete led a successful spin out of their Health Management business in a $600 million deal. Pete has more than 15 years of healthcare experience. Pete is a graduate of Vanderbilt University. He lives in Atlanta with his wife and two children, and plays an active role in youth athletic programs.
Raymond(Ray) Pawlicki, is an innovative leader of people, technology, and process who has held senior management positions with leading global companies including Novartis, Biogen, Cytec Industries, PepsiCo, Citibank, and Hewlett Packard. Ray served as Chief Information Officer and Senior Vice President of Biogen Inc. and was also CIO of Novartis Pharmaceuticals, A.G. where he was instrumental in restructuring the IT organization, and transforming IT into a strategic asset pivotal to the $8 billion biotech company’s success. contributes his expertise as a board member on several organizations for several organizations including Harvard Pilgrim Health Care and UMass Memorial Healthcare. As Chairman of the IT Subcommittee of the Board of Trustees for UMass Memorial Healthcare, Pawlicki is helping redefine IT strategy as a competitive advantage and source of future efficiencies and growth for one of the largest health systems in Massachusetts. Ray received a B.S. in Computer Science from Montclair State University and has contributed to Harvard University Business School’s Executive Education programs as well as the International Institute for Management Development in Lausanne, Switzerland.
Richard Penson is Associate Professor of Medicine at Harvard Medical School, and Clinical Director Medical Gynecologic Oncology at Massachusetts General Hospital. Dr. Penson joined MGH from St Bartholomew's Hospital, London, in 1997 and his practice is devoted almost exclusively to gynecologic oncology with the majority of patients having ovarian cancer. In addition, he attends on the Bigelow General Medical Service at Mass General and does general oncology as Clinical Director Cancer Services at Martha's Vineyard and Nantucket. Dr. Penson sits on the National Gynecologic Oncology Group (NRG) committees for ovarian cancer and quality of life research, and the NCCN Ovarian Committee. Dr. Penson serves as chairman for panels C, and F of the Institutional Review Board of Dana-Farber/Partners CancerCare.
Praveen is President and CEO of Morphic Therapeutic Inc. Previously, he was Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, a position in which he served from 2002 until the company’s acquisition by Merck in 2015. In his time at Cubist, he served in the clinical group working on the Cubicin NDA (skin and skin structure infections) and sNDA (Staph. Bacteremia and Endocarditis) teams. Prior to joining Cubist, Dr. Tipirneni worked at Sun Microsystems in corporate strategy, Covad Communications in Corporate Strategy, and Deltagen in business development. He also served time as a 1st Lieutenant in the U.S. Army. Dr. Tipirneni received a bachelor’s degree from MIT in mechanical engineering and an M.D. from McGill University. After completing his post-graduate residency in Internal Medicine at University of Illinois, Chicago, he received his MBA from the University of Pennsylvania’s Wharton School of Business in healthcare finance.
Juswinder Singh Ph.D. is a scientist, innovator and entrepreneur. He has founded two companies Avila Therapeutics (Acquired by Celgene 2012) and Ankaa Therapeutics a start-up company focused on the development of drugs to treat drug resistance. He has recently been awarded the 2016 ACS George and Christine Sosnovsky award for outstanding contributions to cancer research. In 2016 he was awarded the Excellence in Innovation Award by the Chinese-American Biomedical Association. Dr. Singh received his PhD in rational drug design at the University of London followed by a post-doctoral fellowship at University College London. He has published more than fifty papers in peer-reviewed journals and one book, holds eleven patents, and is a Senior Editor of the journal, Chemical Biology and Drug Design.